Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing

Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose‐adjusted trough concentrations of tacrolimus as compared with those who are CYP...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Pharmacol Ther
Main Authors: Birdwell, KA, Decker, B, Barbarino, JM, Peterson, JF, Stein, CM, Sadee, W, Wang, D, Vinks, AA, He, Y, Swen, JJ, Leeder, JS, van Schaik, RHN, Thummel, KE, Klein, TE, Caudle, KE, MacPhee, IAM
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2015
Assuntos:
CPIC Guideline
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4481158/
https://ncbi.nlm.nih.gov/pubmed/25801146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.113
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados